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Background: We conducted a prospective phase II study of cispla-
tin plus cremophor EL-free paclitaxel (Genexol-PM) in patients with 
unresectable thymic epithelial tumors to determine the efﬁcacy and 
tolerability of the combination therapy.
Methods: Patients were treated with cisplatin (70 mg/m2) and 
Genexol-PM (230 mg/m2) on day 1 of a 3-week cycle as ﬁrst-line 
palliative chemotherapy. The primary end point of this study was 
objective response rate, and the secondary end points included tox-
icity, progression-free survival (PFS), overall survival, correlation 
between early 18F-fluorodeoxyglucose positron emission tomog-
raphy/computed tomography response and PFS, and correlation 
between baseline flurododeoxyglucose uptake and histology.
Results: Forty-two patients with unresectable thymoma (n = 14) or 
thymic carcinoma (n = 28) were enrolled between May 2012 and 
October 2014. The median age was 59 years (range: 25–77) and 30 
patients (71%) were male, and 39 patients (93%) had an ECOG PS 
of 1. The median number of treatment cycles was six (range: 1–6). 
For 40 assessable patients, the objective response rate was 62.5% 
(95% conﬁdence interval [CI]: 47.6–77.4) with rates of 46% (95% 
CI: 23.3–76.9) for advanced thymoma (n = 13) and 70% (95% CI: 
52.0–82.1) for thymic carcinoma (n = 27). With a median follow-up 
of 15.5 months, the median PFS for all 42 patients was 9.8 months 
(11.4 months for thymoma versus 8.1 months for thymic carcinoma). 
The 2-year overall survival was 77.9% for thymoma and 65.9% for 
thymic carcinoma. There were no treatment-related deaths. The most 
common grade 3 and 4 treatment-related adverse event was neutro-
penia in 11 patients (26%). Eight patients (19%) experienced grade 
2 hypersensitivity reactions. There was no correlation between early 
positron emission tomography response and PFS, but tumor histol-
ogy (thymoma versus thymic carcinoma) was correlated with SUV
max
 
before chemotherapy.
Conclusions: These data suggest that combination of cisplatin and 
Genexol-PM is highly effective and tolerable for the treatment of 
unresectable thymic epithelial tumors.
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Although thymic epithelial tumors (TETs) are the most common tumors of the anterior mediastinum,1 they are 
rare, with an overall incidence of 0.15 per 100,000 person-
years.2 TETs are classiﬁed as either thymoma (subclassi-
ﬁed into types A, AB, B1, B2, and B3) or thymic carcinoma 
according to morphological features, cytological atypia, and 
lack of organotypia with the thymus.3 The prognosis of TETs 
is strongly associated with the World Health Organization 
histologic classiﬁcation, Masaoka stage, and resectability.3–5 
Although both types of TET originate from the same neo-
plastic cells, thymic carcinomas are more aggressive and less 
responsive to chemotherapy.3,4,6
Surgical resection is the primary treatment option for 
TETs, with complete resection resulting in the best progno-
sis.4 However, TETs usually present an advanced stage due to 
the lack of symptoms at an early stage. Patients with unresect-
able TETs are usually treated with palliative chemotherapy. 
The standard chemotherapy for TETs remains controversial, 
but there was a general consensus that anthracycline-based 
regimens with platinum should be considered key regimens.7 
However, recent pooled analysis showed no signiﬁcant differ-
ence in terms of response rate between anthracycline and non-
anthracycline-based chemotherapy (41.8% versus 40.9%).8 
The response rates of cisplatin and carboplatin-based chemo-
therapy were 53.6% and 32.8%, respectively (p = 0.0029).8 
Given that cisplatin is a key drug for treatment of TETs, the 
use of other agents that exhibit synergistic activity in combi-
nation with cisplatin has been considered.9–11
Genexol-PM (Samyang Co., Seoul, Korea) is a ster-
ile lyophilized polymeric micellar formulation of paclitaxel 
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without Cremorphor EL (CrEL, polyoxyethylated castor 
oil). CrEL has been known to induce histamine release and 
may therefore be responsible for hypersensitivity reaction.12 
In a phase II trial of non–small-cell lung cancer patients, 
Genexol-PM in combination with cisplatin showed signiﬁ-
cant anticancer activity with an overall response rate of 37.7% 
and relatively good tolerability.13 We designed an open-label 
phase II study of cisplatin and Cremorphor EL-free paclitaxel 
in patients with unresectable TETs to determine the efﬁcacy 
and toxicity of the treatment. The predictive value of early 
response using 18F-fluorodeoxyglucose (FDG) positron emis-
sion tomography (PET) was also assessed.
PATIENTS AND METHODS
This open-label, single-arm, phase II trial was con-
ducted at Samsung Medical Center in the Republic of Korea. 
The protocol and all related materials were approved by 
the institutional review boards. The study was conducted in 
accordance with the Declaration of Helsinki and International 
Conference on Harmonization Guidelines for Good Clinical 
Practice. Written informed consent was obtained from all 
patients before participation.
Patients
Study population consisted of patients aged 18 years or 
older with histologically conﬁrmed TETs that were not ame-
nable to curative surgery or recurrent/metastatic TETs, with 
measurable disease according to Response Evaluation Criteria 
in Solid Tumors (RECIST) version 1.1. All eligible patients 
were required to have an ECOG performance status of 0 or 1 
and adequate bone marrow reserve (absolute neutrophil count 
1500 greater than or equal to cells/μl and platelet count of 
100,000 greater than or equal to cells/μl), renal function (cre-
atinine less than or equal to 2.0 mg/dl), and hepatic function 
(serum bilirubin, transaminase, alkaline phosphatase less than 
or equal to 2.0 times the upper limit of normal). Patients were 
not eligible if they had prior malignancies, unless these were 
curatively treated with no evidence of recurrence within the 
previous 5 years. Patients must not have received prior pal-
liative chemotherapy. However, patients who had previously 
received surgery, radiotherapy, or preoperative or adjuvant 
chemotherapy were allowed to enroll.
Treatment Regimen
Patients received intravenous (IV) Genexol-PM at a dose 
of 230 mg/m2 over 3 hours, followed by cisplatin 70 mg/m2 IV 
over 1 hour with adequate hydration. All patients received 
premedication with the 5-HT3 antagonist, aprepitant and 
dexamethasone (day 1: 20 mg; day 2–4: 8 mg). Granulocyte 
colony-stimulating factor was not administered prophylac-
tically. Treatment was repeated every 3 weeks until disease 
progression, intolerance, or completion of the maximum six 
cycles.
Toxic effects were assessed at baseline and within 3 days 
of the next treatment date. Dose modiﬁcation was executed 
according to the severity of hematological and nonhemato-
logic toxic effects other than anorexia, nausea, and alopecia. 
A 20% dose reduction of Genexol-PM was required in cases 
with grade 4 hematologic toxicity, any grade of febrile neu-
tropenia, any grade hematologic toxicity that delayed the next 
cycle of chemotherapy for more than 1 week, grade 2 periph-
eral neuropathy, or grade 3 nonhematologic toxic effects other 
than neurological toxicity. If grade 3/4 neurological toxicity 
or grade 4 nonhematologic toxic events occurred, the patient 
was excluded from the study. If any of these adverse events 
recurred after the ﬁrst dose reduction, a further dose reduc-
tion of 10% was recommended. Cisplatin dose reduction was 
carried out according to the grade of renal toxicity. No dose 
escalations were allowed. A maximum of two dose reductions 
were allowed, and any patient who required a third dose reduc-
tion was removed from the study and treated at the investiga-
tor’s discretion.
Evaluation
Baseline assessments included history and physical 
examination, complete blood count, chemical proﬁle, chest 
X-ray, thoracic multi-sliced spiral computed tomography (CT), 
18F-FDG PET, and other staging procedures, such as bone 
scan and magnetic resonance imaging if indicated. Evaluation 
during treatment included history and physical examination, 
complete blood count, and chemical proﬁle before each cycle. 
Disease assessment was performed with PET and thoracic CT 
after the second cycle, and thereafter thoracic CT scan was 
repeated every two cycles. After six cycles, patients had a tho-
racic CT every 3 months until disease progression. Treatment 
response was evaluated using RECIST 1.1 criteria. All response 
evaluations were performed by independent intramural review. 
Adverse events were recorded and graded using the National 
Cancer Institute-Common Toxicity Criteria version 4.0.
We chose to assess FDG using SUV
max
 (maximum stan-
dardized uptake value) because this is the most commonly 
used method for evaluating FDG uptake. The SUV
max
 before 
chemotherapy was obtained in the single most metabolically 
active lesion, and changes in PET parameters were used for 
analysis as follows:
∆SUV SUV beforechemotherapy
SUV after nd chemother
max max
max
= ( )
2 apy( )
% /∆ ∆SUV SUV SUV before chemotherapymax max max= × ( )100
The primary end point of this study was objective 
response rate (ORR), and secondary end points included toxic-
ity, progression-free survival (PFS), and overall survival (OS). 
We also evaluated the predictive value of the early response 
using PET (%ΔSUV
max
).
The ORR was deﬁned as the proportion of patients 
with complete or partial response (PR) at any point. OS was 
deﬁned as time from the on-study date to death as a result of 
any cause, with censoring at the date of the ﬁnal follow-up in 
surviving patients. PFS was deﬁned as time from the on-study 
date to date of disease progression, with censoring at the date 
of the ﬁnal follow-up if the patient had not progressed.
Statistical Analysis
The sample size was calculated according to a Simon’s 
two-stage design, with an alpha error of 0.05 and a beta error of 
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0.2 (power 0.8). The activity of chemotherapy was considered 
not clinically signiﬁcant if the ORR was lower than 30% (H0; 
based on historical data), and treatment was considered promis-
ing if the ORR was higher than 50% (H1). Under these assump-
tions, 16 patients were recruited for the ﬁrst stage; if at least 
seven objective responses were achieved, the study proceeded 
to the second stage. The target sample size was 43 patients, of 
whom 39 were expected to be evaluable for outcome.
The Mann–Whitney U test for unpaired observations 
was used to compare the levels of SUV
max
 in thymoma and 
thymic carcinoma. Metabolic response was deﬁned as a 
greater than 30% decrease in baseline SUV
max
, based on 
PET response Criteria in Solid Tumors.14 Lack of metabolic 
response was deﬁned as a less than 30% decrease in SUV
max
 or 
increase from baseline. The comparisons of ΔSUV
max
 between 
two groups (metabolic responder versus nonresponder) were 
performed using the Mann–Whitney U test.
ORRs are presented with 95% exact binomial conﬁ-
dence intervals (CIs). PFS and OS are presented using the 
method of Kaplan–Meier and compared using the log-rank 
test. All p values are two sided, and a level of 5% was con-
sidered statistically signiﬁcant. All statistical analyses were 
performed using SPSS statistical software version 21 (IBM, 
Armonk, NY).
RESULTS
From May 2012 to October 2014, 44 patients signed 
the informed consent form and were enrolled. One patient 
withdrew consent before treatment, and the other patient was 
excluded due to misdiagnosis. A total of 42 patients received 
at least one cycle of treatment. Two patients discontinued 
chemotherapy after one cycle without response assessment. 
Thus, 40 patients were included in response evaluation, and all 
42 patients who received at least one cycle of chemotherapy 
were included for toxicity evaluation and survival analysis.
Patient Characteristics
The median age of all patients was 59 years (range: 
25–77), 30 patients (71%) were male, and 39 patients (93%) 
had an ECOG performance score of 1. Thirteen (93%) of 
14 patients with thymoma were World Health Organization 
histologic type B2 or B3, and 17 (61%) of 28 patients with 
thymic carcinoma had well-differentiated squamous cell car-
cinoma. Thirteen patients with thymoma had stage IV disease 
at enrollment (6 stage IVa and 7 stage IVb), and 25 patients 
with thymic carcinoma presented with stage IV disease 
(18 stage IVa and 7 stage IVb). Eight (57%) cases of thymoma 
and nine (32%) of thymic carcinoma were recurrent TETs, all 
of which were Masaoka stages IV). The most common sites 
of metastasis were pleura (64%) and lymph nodes (43%). 
Seventeen patients (41%) had received surgery with cura-
tive intent, and 10 patients (24%) had received radiotherapy. 
Eight patients (19%) had received prior chemotherapy as fol-
lows: six patients with adjuvant PAC (cisplatin, doxorubicin, 
cyclophosphamide), one patient with neoadjuvant cisplatin 
plus docetaxel, and one patient with neoadjuvant cisplatin 
plus docetaxel followed by adjuvant PAC. The median chemo-
therapy-free interval for eight patients previously treated with 
chemotherapy was 3.3 years (range: 0.8–11.3). There were 
no statistically signiﬁcant differences between thymoma and 
thymic carcinoma in terms of age, sex, ECOG PS, stage, or 
previous treatment (Table 1).
Treatment Response and Survival
Among 16 patients who were recruited for the ﬁrst 
stage, 12 patients (75%) showed objective response, and the 
study proceeded to the second stage. Overall, 42 patients 
received a median of six cycles (range: 1–6) of chemotherapy. 
Of the 40 patients evaluable, response rates for TETs were 
as follows: complete response, 0 patients; PR, 25 patients; 
stable disease (SD), 13 patients; progressive disease (PD), two 
patients. The ORR for TETs was 62.5% (95% CI: 47.6–77.4). 
Among patients with thymoma and thymic carcinoma, ORRs 
were 46% (95% CI: 23.3–76.9) and 70% (95% CI: 52.0–82.1), 
respectively (Table 2). For 32 patients who had not received 
prior chemotherapy, ORRs was 65.6% (95% CI: 38.5–82.2) 
TABLE 1.  Baseline Characteristics of Patients
Thymoma 
(n = 14)
Thymic  
Carcinoma 
(n = 28)
Total  
(n = 42)
Age (year), median 57 (25–73) 60 (29–77) 59 (25–77)
Sex
  Male 10 (71%) 20 (71%) 30 (71%)
  Female 4 (29%) 8 (29%) 12 (29%)
ECOG PS
  0 1 (7%) 2 (7%) 3 (7%)
  1 14 (93%) 26 (93%) 39 (93%)
Histologic type, thymoma
  B1 1 (7%) - 1 (7%)
  B2 5 (36%) - 5 (36%)
  B3 8 (57%) - 8 (57%)
Histologic type, thymic carcinoma
  Well differentiated, squamous - 17 (61%) 17 (61%)
  Poorly differentiated, 
squamous
- 7 (25%) 7 (25%)
  Undifferentiated - 4 (14%) 4 (14%)
Stage
  III 1 (7%) 3 (11%) 4 (10%)
  IVa 6 (43%) 18 (64%) 24 (57%)
  IVb 7 (50%) 7 (25%) 14 (33%)
Metastasis site
  Pleura 10 (71%) 17 (61%) 27 (64%)
  Lung 4 (29%) 9 (32%) 13 (31%)
  Lymph node 4 (29%) 14 (50%) 18 (43%)
  Soft tissue 1 (7%) 1 (4%) 2 (5%)
  Liver 1 (7%) 2 (7%) 3 (7%)
  Bone 1 (7%) 6 (21%) 7 (17%)
Prior therapy
  Surgery 8 (57%) 9 (32%) 17 (41%)
  Radiotherapy 3 (21%) 7 (25%) 10 (24%)
  Chemotherapy 4 (29%) 4 (14%) 8 (19%)
  Recurrence 8 (57%) 9 (32%) 17 (41%)
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and there was no difference in response rate between thy-
moma and thymic carcinoma (66.7% [95% CI: 29.0–100.0] 
versus 65.2% [95% CI: 45.0–82.5]).
With a median follow-up of 15.5 months, median PFS for 
all 42 patients was 9.8 months (95% CI: 6.8–12.8). According 
to the histology, there was no signiﬁcant difference between 
thymoma and thymic carcinoma; median PFS was 11.4 months 
(95% CI: 10.6–12.1) for thymoma versus 8.1 months (95% CI: 
6.3–10.0) for thymic carcinoma (Fig. 1). The median PFS for 
32 chemo-naïve patients was 10.2 months (95% CI: 5.9–14.4) 
and median PFS of thymoma patients was longer than those of 
thymic carcinoma (14.0 months versus 7.8 months).
At the time of data cutoff (March 30, 2015), two patients 
(14%) with thymoma and four patients (14%) with thymic 
carcinoma had died. The median OS has not yet been reached 
in either histology group. The 2-year OS was 77.9% for thy-
moma and 65.9% for thymic carcinoma. The two patients with 
thymoma underwent surgery after chemotherapy and com-
plete resection was performed.
PET scan was performed in 29 patients (10 with thy-
moma, 19 with thymic carcinoma). The SUV
max
 of the 
thymic carcinomas (median 9.3, range: 4.1–18.4) was signiﬁ-
cantly higher than that of the thymomas (median 5.1, range: 
4.5–17.0; p = 0.021). Among 29 patients, there were 17 with 
PR, 10 with SD, and two with PD, according to RECIST 1.1. 
The %ΔSUV
max
 of PR and SD groups was 51.3 ± 20% and 
39.1 ± 21%, respectively, which was not statistically signiﬁ-
cant (p = 0.115). The mean %ΔSUV
max
 of two patients with 
PD was 39.5%. In terms of early metabolic response, there 
were 23 responders and six nonresponders according to PET 
response Criteria in Solid Tumors criteria.14 The %ΔSUV
max
 
of responder and nonresponder groups was 55.1 ± 13% and 
12.4 ± 9%, respectively (p < 0.001). However, there was no 
signiﬁcant difference in PFS between metabolic responders 
and nonresponders (median 9.2 months, 95% CI: 6.7–11.6 
versus 12.7 months, 95% CI: 3.7–21.6, p = 0.232).
Toxicities
Of 42 patients, 31 patients (73.8%) completed six cycles 
of chemotherapy. The reasons for discontinuation of treatment 
included toxicities in four patients (9.5%), patient withdrawal 
TABLE 2.  Clinical Activity of Cisplatin/Paclitaxel Chemotherapy in Thymic Epithelial Tumors
Thymoma (n = 13) Thymic Carcinoma (n = 27) Total (n = 40)
Patients (%) (95% CI) Patients (%) (95% CI) Patients (%) (95% CI)
Objective responsea 6 (46%) (23.3–76.9) 19 (70%) (52.0–82.1) 25 (62.5%) (47.6–77.4)
Stable disease 7 (54%) (23.1–76.7) 6 (22%) (3.8–40.6) 13 (32.5%) (17.6–52.3)
Progressive disease 0 (0%) (-) 2 (8%) (0–14.8) 2 (5.0%) (0–12.4)
aObjective response includes only partial response, there was no complete response.
fIGURE 1. A, Progression-free survival of thymic epithelial tumors (median PFS: 9.8 months, 95% CI: 6.8–12.8). B, 
Progression-free survival according to histology (median PFS: 11.4 months, 95% CI: 10.6–12.1 in thymoma versus 8.1 months, 
95% CI: 6.3–10.0 in thymic carcinoma; p = 0.093). PFS, progression-free survival; 95% CI, 95% confidence interval.
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in three patients (7.1%), disease progression in two patients 
(4.8%), and curative surgery after four cycles of chemother-
apy in two patients (4.8%). Three patients withdrawal consent 
discontinued treatment after 1, 2, 5 cycles of chemotherapy, 
respectively. Adverse events that led to treatment discontin-
uation were grade 3 neuropathy (two patients) and grade 3 
febrile neutropenia (two patients).
The hematological and nonhematologic toxic effects for 
each patient are listed in Table 3. The most common hema-
tological toxicity was neutropenia. Grade 3/4 neutropenia 
occurred in 11 patients (26%), seven of whom experienced 
febrile neutropenia. The most common nonhematologic toxici-
ties included alopecia (76%), cholesterol elevation (33%), and 
peripheral neuropathy (57%). As a result of peripheral neuropa-
thy, two patients (5%) were excluded from the study, and seven 
patients (17%) required dose reduction of paclitaxel. Among 
nine patients (21%) who experienced peripheral neuropathy 
more than grade 2, only one patient was previously exposed to 
platinum-based chemotherapy. Overall, 15 (36%) of 42 patients 
required dose reduction: 12 (29%) for paclitaxel, including one 
(2%) who needed two reductions in dose level, and 10 (24%) 
for cisplatin. Toxic effects resulting in a dose reduction included 
neutropenia, febrile neutropenia, peripheral neuropathy, and 
fatigue. There were no treatment-related deaths.
DISCUSSION
A few prospective trials have attempted to deﬁne active 
chemotherapeutic regimens for TETs (Table 4). Until now, the 
standard chemotherapy for TETs remains unclear, although 
anthracycline-based regimens combined with platinum such 
as ADOC (doxorubicin, cisplatin, vincristine, cyclophospha-
mide) or PAC (cisplatin, doxorubicin, cyclophosphamide) 
have traditionally been used.16 Loehrer et al.18 reported that 
the ORR of PAC chemotherapy was 70% with a median 
survival time of 93 months in 23 patients with unresectable 
TETs. Dose-dense chemotherapy, such as CODE (cisplatin, 
vincristine, doxorubicin, etoposide) with granulocyte colony-
stimulating factor support, has also demonstrated activity 
against TETs, with an ORR of 62%.22
However, anthracyclines are known to be associated 
with severe myelosuppression and cardiomyopathy, espe-
cially when combined with radiotherapy.28 Thus, nonanthra-
cycline regimens are appealing. In one study conducted by 
ECOG, 38 patients with octreotide-positive imaging were 
treated with octreotide with or without prednisolone. In that 
trial, there were two CRs and 10 PRs (ORR: 30%).20 Palmieri 
et al.23 reported an ORR of 40% in 20 patients treated with 
capecitabine and gemcitabine. A phase II study of VIP (etopo-
side, ifosfamide, cisplatin) reported a response rate of 25%.10
In this study, cisplatin and paclitaxel resulted in a high 
response rate of 62.5%. The median PFS was greater than 
8 months, even for thymic carcinoma. It has been reported that 
thymoma has a better prognosis and a more sensitive response 
to chemotherapy than thymic carcinoma.4,6 We found that the 
response rate for thymic carcinoma was higher than that for thy-
moma. However, among 32 patients who never received prior 
chemotherapy, the response rate was similar between thymoma 
and thymic carcinoma (67% versus 65%). Given the limitation 
of small number of patients for each arm, a possible explanation 
for these ﬁndings is that a higher proportion of patients with thy-
moma compared with thymic carcinoma was exposed to previ-
ous chemotherapy (31% versus 15%). In contrast, Park et al.11 
reported a numerically higher response rate in thymic carcinoma 
than thymoma (67% versus 56%) using a cisplatin and docetaxel 
combination as neoadjuvant chemotherapy. Thus, additional 
studies are needed to determine whether paclitaxel or taxane has 
better efﬁcacy in thymic carcinoma than in thymoma.
Two recent reports of phase II study with carboplatin and 
paclitaxel for thymic carcinoma showed ORRs of 22 and 36%, 
respectively, and concluded that nonanthracycline-containing 
containing regimens are inferior to anthracycline-containing 
regimens.6,18,26,29 However, a prospective study conducted by 
the EORTC group demonstrated that induction chemotherapy 
followed by curative-intent treatment involving cisplatin and 
etoposide chemotherapy achieved a 56% response rate in 
patients with advanced thymoma.17 Recent pooled analysis 
also demonstrated no signiﬁcant difference in response rate 
between anthracycline-containing and nonanthracycline-con-
taining regimens using platinum-based chemotherapy (ORR: 
33/79 [41.8%] versus 52/127 [40.9%]) in 206 patients from 
10 studies.8 Given the high response rate of this study and pre-
vious study from our institute, combination of cisplatin and 
taxane regimens are highly effective.11
In terms of safety, major adverse events in this study 
were myelosuppression, neuropathy, and hypersensitivity 
reaction. Bone marrow suppression with grade 3/4 neutrope-
nia was observed in 11 patients (26%), including seven (17%) 
with febrile neutropenia. The incidence of grade 3/4 neutrope-
nia was lower than in previous studies using carboplatin and 
paclitaxel, but febrile neutropenia occurred more frequently.6,26 
Given the relative high incidence of febrile neutropenia with 
this regimen, prophylactic use of granulocyte colony-stimu-
lating factor should be considered. Neurotoxicity may be a 
disadvantage of platinum-containing paclitaxel regimens, but 
TABLE 3.  Treatment-Related Adverse Events (n = 42)
Grade (CTCAE 4.0) 1 2 3 4 Grade 3/4
Neutropenia 0 2 3 1 4 (9.5%)
Febrile neutropenia NA NA 7 0 7 (16.7%)
Thrombocytopenia 1 2 0 0 0
Alopecia 0 32 0 0 0
Peripheral sensory neuropathy 15 7 2 0 2 (4.7%)
Allergic reaction 0 2 0 0 0
Myalgia 3 1 0 0 0
Arthralgia 1 0 0 0 0
Constipation 2 1 0 0 0
Diarrhea 0 2 0 0 0
Cholesterol elevation 14 0 0 0 0
Aspartate aminotransferase 
elevation
1 0 0 0 0
Alanine aminotransferase 
elevation
1 0 0 0 0
Hypersensitivity reaction 8 8 0 0 0
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carboplatin-containing regimens have shown a higher risk 
of peripheral neuropathy than those with cisplatin.30 In this 
study, all-grade neuropathy was observed in 57% of patients, 
but only two patients (5%) had grade 3 neuropathy. It is hard 
to make a direct comparison, current study showed less severe 
peripheral neuropathy compared with other previous studies 
using carboplatin and paclitaxel.6,26 The advantage of CrEL-
free paclitaxel over conventional paclitaxel was expected to 
be reduced hypersensitivity reaction. Although hypersensitiv-
ity reactions were not observed in previous phase I studies, 
subsequent phase II studies noted relatively high risk of hyper-
sensitivity reaction.13 In this study, there was no grade 3/4 
hypersensitivity reaction, but 19% of patients experienced a 
grade 2 hypersensitivity reaction, suggesting that hypersensi-
tivity reactions cannot be completely avoided by using CrEL-
free paclitaxel. In terms of hypersensitivity, use of CrEL-free 
paclitaxel rather than conventional paclitaxel cannot be justi-
ﬁed, and safety of CrEL-free paclitaxel should be evaluated 
thoroughly in future studies.
Our study was unique because we evaluated the predic-
tive value of early response to PET and the correlation between 
tumor SUV
max
 and histologic type. Sung et al.31 demonstrated 
a signiﬁcant difference in SUV
max
 between thymoma and thy-
mic carcinoma. The studies of Benveniste et al. and Luzzi 
et al. identiﬁed an SUV
max
 cutoff value of 5 and 6, respectively, 
for thymoma and thymic carcinoma.32,33 The current study is 
in agreement with previous reports that a higher FDG uptake 
is associated with thymic carcinoma rather than thymoma. 
Several studies have shown a correlation between SUV and 
tumor proliferation, indicating that early reduction of FDG 
uptake during treatment predicts therapy response.34 Thomas 
et al.35 and Kaira et al.36 showed that early metabolic response 
closely correlates with outcome of therapy in unresectable 
TETs. We did not ﬁnd any correlation between early PET 
response and PFS according to %ΔSUV
max.
 In this study, some 
patients referred from other hospital after performing baseline 
PET CT. Due to only 69% of patients were included in PET 
response assessment, our PET result could be biased. Further 
exploration with large number of patients should be needed to 
determine the exact role of PET as early response predictor.
Given the rarity of TETs, a large prospective random-
ized clinical trial is unlikely to be performed.8,11,17 The current 
study suggests that Genexol-PM and cisplatin showed com-
parable efﬁcacy to those of anthracycline-based regimens and 
was tolerable with respect to therapy-related adverse effects. 
In conclusion, combination of cisplatin and cremorphor 
EL-free paclitaxel (Genexol-PM) is highly effective and toler-
able for the treatment of unresectable TETs.
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